Aspirin and P2Y12 inhibitors in treating COVID-19

Eur J Intern Med. 2023 Apr:110:101-103. doi: 10.1016/j.ejim.2022.11.027. Epub 2022 Nov 23.

Authors

Amirmohammad Khalaji¹, Amir Hossein Behnoush¹, Soheil Peiman²

Affiliations

¹ School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Department of Internal Medicine, AdventHealth Orlando hospital, Orlando, FL, United States. Electronic address: [email protected].

No abstract available

Keywords: Aspirin; COVID-19; Meta-analysis; P2Y12 inhibitors; Platelet aggregation inhibitors.

Publication types

Letter
Comment

MeSH terms

Aspirin* / therapeutic use
Blood Platelets
COVID-19*
Humans
Platelet Aggregation Inhibitors / pharmacology
Platelet Aggregation Inhibitors / therapeutic use
Purinergic P2Y Receptor Antagonists / pharmacology
Purinergic P2Y Receptor Antagonists / therapeutic use
Ticagrelor

Substances

Aspirin
Platelet Aggregation Inhibitors
Ticagrelor
Purinergic P2Y Receptor Antagonists